Geode Capital Management LLC Has $3.19 Billion Stock Holdings in Pfizer Inc. (NYSE:PFE)

Geode Capital Management LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 120,589,782 shares of the biopharmaceutical company's stock after purchasing an additional 2,923,537 shares during the period. Geode Capital Management LLC owned approximately 2.13% of Pfizer worth $3,190,131,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer in the 4th quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Finally, Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $31.92.

Remove Ads

Pfizer Trading Down 1.5 %

Shares of PFE traded down $0.38 during trading hours on Thursday, reaching $24.33. The stock had a trading volume of 37,619,637 shares, compared to its average volume of 39,249,333. The company has a market cap of $137.96 billion, a P/E ratio of 17.25, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52 week low of $24.31 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average of $25.98 and a 200 day moving average of $26.83.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.